Cerebrospinal fluid neuron-specific enolase: A further marker of Alzheimer's disease?

Functional Neurology

Volumn 23, Issue 2, 2008, Pages 93-96

  Palumbo, Barbara ^a   Siepi, Donatella ^a   Sabalich, Isabella ^a   Tranfaglia, Cristina ^a   Parnetti, Lucilla ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Alzheimer's disease; Cerebrospinal fluid; Fronto temporal dementia; Lewy body disease; Mild cognitive impairment; Neuron specific enolase

Indexed keywords

NEURON SPECIFIC ENOLASE;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; MAJOR CLINICAL STUDY; MALE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COGNITION DISORDERS; DEMENTIA; FEMALE; FRONTAL LOBE; HUMANS; LEWY BODY DISEASE; MALE; PEPTIDE FRAGMENTS; PHOSPHOPYRUVATE HYDRATASE; REFERENCE VALUES; TAU PROTEINS; TEMPORAL LOBE;

EID: 50849136540     PISSN: 03935264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Andreasen N, Minthon L, Davidsson P et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001;58:373-379
2. Blennow K, Vanmechelen E, Hampel H. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 2001;24:87-97
3. Galasko D, Chang L, Motter R et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to Apolipoprotein E genotype. Arch Neurol 1998;55:937-945
4. Tapiola T, Pirttilä T, Mehta PD, Alafuzoff I, Lehtovirta M, Soininen H. Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease. Neurobiol Aging 2000;21:735-740
5. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-234
6. Mauri M, Sinforiani E, Bono G et al. Interaction between Apolipoprotein epsilon 4 and traumatic brain injury in patients with Alzheimer's disease and mild cognitive impairment. Funct Neurol 2006;21:223-228
7. Bowman FH, van der Flier WM, Schoonenboom NS et al. Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology 2007;69:1006-1011
8. Parnetti L, Palombo B, Cardinali L et al. Cerebrospinal fluid neuron-specific enolase in Alzheimer's disease and vascular dementia. Neurosci Lett 1995;183:43-45
9. Infante JR, Martínez A, Ochoa J et al. Levels of S-100 and neuron specific enolase in cerebrospinal fluid from subjects with neurological pathologies. Rev Esp Med Nucl 2003;22:238-243
10. Harrington CR, Quinn GB, Hurt J, Day IN, Wischik CM. Characterisation of an epitope specific to the neuron-specific isoform of human enolase recognised by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of beta/A4-protein. Biochim Biophys Acta 1993;1158:120-128
11. McKhann G, Drachmann D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944
12. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308
13. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry 1994;57:416-418
14. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 2006;9:417-423
15. Vanderstichele H, Van Kerschaver E, Hesse C et al. Standardization of measurement of beta-amyloid (1-42) in cerebrospinal fluid and plasma. Amyloid 2000;7:245-258
16. Vanmechelen E, Vanderstichele H, Davidsson P et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49-52
17. Blennow K, Wallin A, Ekman R. Neuron specific enolase in cerebrospinal fluid: a biochemical marker for neuronal degeneration in dementia disorders? J Neural Transm Park Dis Dement Sect 1994;8:183-191
18. Hwang DY, Cho JS, Lee HS et al. Aberrant expressions of pathogenic phenotype in Alzheimer's diseased transgenic mice carrying NSE-controlled APPsw. Exp Neurol 2004;186:20-32
19. Savage MJ, Lin YG, Ciallella JR, Flood DG, Scott RW. Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J Neurosci 2002;22:3376-3385
20. Jee SW, Cho JS, Kim CK et al. Oligonucleotide-based analysis of differentially expressed genes in hippocampus of transgenic mice expressing NSe-controlled APPsw. Neurochem Res 2006;31:1035-1044